Reclassifying a medical device under the MDR is one of the most destabilising situations a manufacturer can face. A device marketed for ten years as class I under Directive 93/42/EEC that becomes class IIa under the MDR: it is the entire regulatory approach that changes, not just a few documents to update.
The most frequent reclassifications under the MDR
Software. Rule 11 of Annex VIII has reclassified thousands of software products from class I to higher classes. Diagnostic decision-support software that was class I under the Directive may be IIa or IIb under the MDR depending on the potential clinical impact of its errors.
Reusable surgical instruments. Some instruments previously in class I have been reclassified as IIa as a result of Rule 7 of the MDR.
Implantable devices made from resorbable materials. Rule 22 introduced by the MDR has led to reclassifications to class III for certain spinal devices.
What reclassification means in practical terms
The move from class I to class IIa is probably the most structurally significant change: from self-certification, you move to the requirement for a notified body. This change means building or strengthening the QMS in accordance with the requirements of Annex IX, compiling a complete technical file in accordance with Annex II with a substantial clinical evaluation, selecting and contracting with a notified body, and planning for a radically different budget and timeline.
The move from class IIa to IIb does not change the basic procedure (a notified body is still required) but increases the level of requirement for the clinical evaluation and the level of scrutiny the notified body applies to the file.
How to anticipate the transition
The first step is to confirm the new MDR classification as early as possible. If reclassification is confirmed, it is a regulatory reality — denying it or hoping for a different interpretation only reduces the time available to prepare for it.
The second step is to build a transition plan that integrates the MDR certification activities into the company’s schedule. A Directive certificate valid until 2027 buys time — but that time disappears quickly if the first regulatory actions are not initiated promptly.
The third step is to assess the economic impact. A reclassification from I to IIa represents an investment of 60,000 to 120,000 euros and 18 to 24 months of work. For some low-volume or low-margin devices, this investment must be weighed against the commercial strategy.